Short Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Increases By 609.4%

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 461,661 shares, an increase of 609.4% from the August 15th total of 65,075 shares. Currently, 65.3% of the company’s stock are short sold. Based on an average daily volume of 5,622,745 shares, the days-to-cover ratio is presently 0.1 days.

Aethlon Medical Price Performance

Shares of NASDAQ AEMD traded down $0.03 during mid-day trading on Friday, hitting $1.53. The company had a trading volume of 103,167 shares, compared to its average volume of 3,233,330. The business’s 50-day simple moving average is $2.79 and its 200-day simple moving average is $7.49. Aethlon Medical has a 12 month low of $1.52 and a 12 month high of $41.35. The firm has a market cap of $1.09 million, a P/E ratio of -0.04 and a beta of 1.40.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing the consensus estimate of ($3.92) by ($0.10). As a group, sell-side analysts predict that Aethlon Medical will post -5.74 EPS for the current year.

Institutional Trading of Aethlon Medical

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent reporting period. Institutional investors and hedge funds own 1.99% of the company’s stock.

Analysts Set New Price Targets

AEMD has been the topic of several analyst reports. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Friday, July 17th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $1.50 price objective on shares of Aethlon Medical in a report on Tuesday, August 18th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $1.50.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.